# To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women

> **NCT01904110** · PHASE4 · COMPLETED · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 196 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Risedronate/Cholecalciferol combination(montly)
- **DRUG:** Risedronate/Cholecalciferol combination(weekly)

## Key facts

- **NCT ID:** NCT01904110
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2014-05-29
- **Final completion:** 2016-03-31
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2018-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01904110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01904110, "To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01904110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*